Abstract
The contribution of renal sympathetic nerve activity to the development and progression of resistant hypertension, has been convincingly demonstrated in both preclinical and human experiments. Preclinical experiments in hypertension models of hypertension [5, 6, 14], have successfully used renal denervation as both an experimental tool and a therapeutic strategy, but even earlier, in the absence of appropriate drugs to pharmacologically reduce blood pressure in severely hypertensive patients, therapeutic splanchnicectomy and even radical surgical sympathectomy were used since the 1930s. These surgical techniques have been abandoned due to their severe side effects. Recent studies have further investigated the close relationship between kidneys and brain, and gave light to some important parameters of this transaction. Low frequency stimulation of the sympathetic system resulted in renin excretion only, intermediate frequency stimulation results on decreased urinary sodium excretion and high frequency stimulation, results on direct renal artery vasoconstriction, decrease in renal blood flow and decrease glomerular filtration rate [2, 5, 10].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arndt C, Tefft M, Gehan E, Anderson J, Jenson M, Link M, Donaldson S, Breneman J, Wiener E, Webber B, Maurer H. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. J Pediatr Hematol Oncol. 1997;19(2):124–9.
Barajas L, Muller J. The innervation of the juxtaglomerular apparatus and surrounding tubules: a quantitative analysis by serial section electron microscopy. J Ultrastruct Res. 1973;43(1):107–32.
Carbone PP, Bono V, Frei 3rd E, Brindley CO. Clinical studies with vincristine. Blood. 1963;21:640–7.
Consigny PM, Davalian D, Donn R, Hu J, Rieser M, Stolarik D. Chemical renal denervation in the rat. Cardiovasc Intervent Radiol. 2013;37(1):218–23.
DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004;43(2):147–50.
Doumas M, Papademetriou V, Douma S, Faselis C, Tsioufis K, Gkaliagkousi E, Petidis K, Zamboulis C. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens. 2010;2011:318549.
Earl HM, Connolly S, Latoufis C, Eagle K, Ash CM, Fowler C, Souhami RL. Long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas. Sarcoma. 1998;2:97–105.
Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–7.
Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2011;9756:1903–9.
Gewirtz JR, Bisognano JD. Catheter-based renal sympathetic denervation: a targeted approach to resistant hypertension. Cardiol J. 2011;1:97–102.
Holland JF, Scharlau C, Gailani S, Krant MJ, Olson KB, Horton J, Shnider BI, Lynch JJ, Owens A, Carbone PP, Colsky J, Grob D, Miller SP, Hall TC. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 1973;33(6):1258–64.
Ja'afer FM, Hamdan FB, Mohammed FH. Vincristine-induced neuropathy in rat: electrophysiological and histological study. Exp Brain Res. 2006;173(2):334–45.
Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, Bertog SC. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60(25):2694–5.
Kato T, Kassab S, Wilkins Jr FC, Kirchner KA, Granger JP. Decreased sensitivity to renal interstitial hydrostatic pressure in Dahl salt-sensitive rats. Hypertension. 1994;23(6 Pt 2):1082–6.
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;9671:1275–81.
LeQuesne. Neuropathy due to drugs; diseases of the peripheral nervous system. Peripheral neuropathy. 2nd ed. Philadelphia: WB Saunders Co; 1984. p. 2173–4.
Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. Eur Interv. 2012;​8(1):57–61.
Manning PT, Powers CW, Schmidt RE, Johnson Jr EM. Guanethidine-induced destruction of peripheral sympathetic neurons occurs by an immune-mediated mechanism. J Neurosci. 1983;3(4):714–24.
Mantadakis E, Amoiridis G, Kondi A, Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol. 2007;29(2):130.
Medtronic pr (2014) http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1889335&highlight=.
Moore AS, Norris R, Price G, Nguyen T, Ni M, George R, van Breda K, Duley J, Charles B, Pinkerton RV. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health.
Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol. 1999;39(6):323–30.
Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med. 1974;80(6):733–7.
Stefanadis C. Renal denervation in resistant hypertension: radiofrequency ablation and chemical denervation. Hellenic J Cardiol. 2011;52(6):481–2.
Stefanadis C, Synetos A, Toutouzas K, Tsioufis C, Drakopoulou M, Tsiamis E, Agrogiannis G, Patsouris E, Tousoulis D. Barodenervation of the sympathetic nervous system of the renal artery. A new concept. Int J Cardiol. 2013;168(4):4443–4.
Stefanadis C, Synetos A, Toutouzas K, Tsioufis C, Drakopoulou M, Tsiamis E, Agrogiannis G, Patsouris E, Tousoulis D. New double balloon delivery catheter for chemical denervation of the renal artery with vincristine. Int J Cardiol. 2013;168(4):4346–8.
Stefanadis C, Toutouzas K, Synetos A, Tsioufis C, Karanasos A, Agrogiannis G, Stefanis L, Patsouris E, Tousoulis D. Chemical denervation of the renal artery by vincristine in swine. A new catheter based technique. Int J Cardiol. 2013;167(2):421–5.
Stefanadis C, Toutouzas K, Synetos A, Tsioufis C, Karanasos A, Agrogiannis G, Stefanis L, Patsouris E, Tousoulis D. Effectiveness of the denervation of the renal sympathetic nervous system by vincristine, by a constant flow rate delivery catheter. Int J Cardiol Subm. 2014.
Stefanadis C, Toutouzas K, Vlachopoulos C, Tsioufis C, Synetos A, Pietri P, Tousoulis D, Tsiamis E. Chemical denervation of the renal artery with vincristine for the treatment of resistant arterial hypertension: first-in-man application. Hellenic J Cardiol. 2013;54(4):318–21.
Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64(6):1076–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Toutouzas, K., Synetos, A., Stefanadis, C. (2015). Vincristine Local Delivery for Renal Artery Denervation. In: Heuser, R., Schlaich, M., Sievert, H. (eds) Renal Denervation. Springer, London. https://doi.org/10.1007/978-1-4471-5223-1_14
Download citation
DOI: https://doi.org/10.1007/978-1-4471-5223-1_14
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-5222-4
Online ISBN: 978-1-4471-5223-1
eBook Packages: MedicineMedicine (R0)